FDA Draft Guidance On Decentralized Clinical Trials
Draft Guidance provides recommendations such as design considerations, conduct of remote clinical trial activities, use of digital health technologies to remotely acquire data, roles of the sponsor and investigators, informed consent and institutional review board oversight
Robertm Califf Drug Administration Draft Guidance Decentralized Clinical Trials Decentralized Clinical Digital Health Technologies
Source: natlawreview.com